486 related articles for article (PubMed ID: 18182670)
41. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
42. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
[TBL] [Abstract][Full Text] [Related]
43. Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.
Cosler LE; Sivasubramaniam V; Agboola O; Crawford J; Dale D; Lyman GH
Value Health; 2005; 8(1):47-52. PubMed ID: 15841893
[TBL] [Abstract][Full Text] [Related]
44. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
45. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Skedgel C; Rayson D; Younis T
Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
[TBL] [Abstract][Full Text] [Related]
46. Individual timing of blood counts in G-CSF prophylaxis after myelosuppressive chemotherapy reduces G-CSF injections, blood counts, and costs: a prospective randomized study in children and adolescents.
Ammann RA; Leibundgut K; Hirt A; Ridolfi Lüthy A
Support Care Cancer; 2002 Nov; 10(8):613-8. PubMed ID: 12436219
[TBL] [Abstract][Full Text] [Related]
47. [Pegfilgrastim vs filgrastim in primary prophylaxis of febrile neutropenia in patients with breast cancer after chemotherapy: a cost-effectiveness analysis for Germany].
Sehouli J; Goertz A; Steinle T; Dubois R; Plesnila-Frank C; Lalla A; von Minckwitz G
Dtsch Med Wochenschr; 2010 Mar; 135(9):385-9. PubMed ID: 20180162
[TBL] [Abstract][Full Text] [Related]
48. Cost-effectiveness of different treatment strategies with intrapartum antibiotic prophylaxis to prevent early-onset group B streptococcal disease.
Akker-van Marle ME; Rijnders ME; Dommelen P; Fekkes M; Wouwe JP; Amelink-Verburg MP; Verkerk PH
BJOG; 2005 Jun; 112(6):820-6. PubMed ID: 15924544
[TBL] [Abstract][Full Text] [Related]
49. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
50. Prophylactic antibiotics or G-CSF for the prevention of infections and improvement of survival in cancer patients undergoing chemotherapy.
Herbst C; Naumann F; Kruse EB; Monsef I; Bohlius J; Schulz H; Engert A
Cochrane Database Syst Rev; 2009 Jan; (1):CD007107. PubMed ID: 19160320
[TBL] [Abstract][Full Text] [Related]
51. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
Shochat E; Rom-Kedar V
Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
[TBL] [Abstract][Full Text] [Related]
52. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
[TBL] [Abstract][Full Text] [Related]
53. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
[TBL] [Abstract][Full Text] [Related]
54. Review of the value of colony stimulating factors for prophylaxis of febrile neutropenic episodes in adult patients treated for haematological malignancies.
Levenga TH; Timmer-Bonte JN
Br J Haematol; 2007 Jul; 138(2):146-52. PubMed ID: 17593021
[TBL] [Abstract][Full Text] [Related]
55. A prospective randomised evaluation of G-CSF or G-CSF plus oral antibiotics in chemotherapy-treated patients at high risk of developing febrile neutropenia.
Lalami Y; Paesmans M; Aoun M; Munoz-Bermeo R; Reuss K; Cherifi S; Alexopoulos CG; Klastersky J
Support Care Cancer; 2004 Oct; 12(10):725-30. PubMed ID: 15235901
[TBL] [Abstract][Full Text] [Related]
56. Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.
Silvestris N; Del Re M; Azzariti A; Maiello E; Lombardi L; Cinieri S; Guarini A; Brunetti AE; Delcuratolo S; De Vita F; Pisconti S; Danesi R; Colucci G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S111-7. PubMed ID: 22443211
[TBL] [Abstract][Full Text] [Related]
57. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
[TBL] [Abstract][Full Text] [Related]
58. [Prognostic factors for febrile neutropenia].
Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
60. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
